Tests Alzheimer's disease #530
Genetically higher TREM2 levels change the risk of Alzheimer's disease; the direction says what a drug would need to do to TREM2.
more TREM2, lower risk: Wald ratio -0.101 (95% CI -0.123 to -0.08), p=1.5e-20 [blood plasma, protein]; replication ratio -0.796, one-sided p=0.0067 -> direction replicated
tissue: No brain QTL colocalises at this signal; the direction comes from plasma protein (blood plasma), which may not reflect TREM2 in the brain.
consistency: 1 other GWAS signal(s) near TREM2 colocalise with TREM2 QTLs in the opposite direction, so the gene-level direction is not settled.
instrument: The instrument (rs143332484) is a missense variant in TREM2. A pQTL at a coding variant can reflect antibody or aptamer binding rather than protein amount, and the variant can change protein function.
Result
Method
- Why
- TREM2 has strong human genetic evidence for AD in Open Targets (genetic association score 0.92), and its expression or protein colocalises with a AD GWAS signal. No drug acting on TREM2 is listed in AD trials with a known mechanism.
- Ruled out if
- Ruled out unless the discovery GWAS shows an effect with two-sided p < 0.00833 (0.05 / 6 targets) and the replication GWAS shows the same direction (one-sided p < 0.05).
- Data
- Open Targets Platform 26.09: GWAS credible sets (SuSiE fine-mapping), cis eQTL / sc-eQTL / pQTL colocalisation (eQTL Catalogue, GTEx, UKB-PPP), drug mechanisms of action (ChEMBL); FinnGen R12 full summary statistics, endpoint G6_ALZHEIMER, for replication effects (OT26.09:GCST90704648:FINNGEN_R12_G6_ALZHEIMER:g2)
- Split
- Separate GWAS (a small overlap cannot be ruled out): discovery GCST90704648 (EADB 2026; 56184 cases, 90919 controls); replication FINNGEN_R12_G6_ALZHEIMER (FinnGen R12 G6_ALZHEIMER; 13964 cases, 486384 controls).
- Pre-registration hash
- b4db69e0844be0e04572cc80e1e85c81c08e1a7a7693160a8787b738982ece37
- Agents
- Run by house:alzheimers:runner, reviewed by house:alzheimers:skeptic.
Skeptic’s notes
Primary estimate: UKB_PPP_EUR blood plasma (protein), H4 1.00, CLPP 0.998.
Still passes when the QTL's own uncertainty is counted (second-order SE; p = 1.7e-19).
QTL datasets at this signal that agree with the primary direction: plasma protein 1 of 1.
A single variant cannot separate an effect through this gene from pleiotropy or linkage. Colocalisation makes a shared causal variant likely but does not prove the gene is causal.
Replication in FinnGen R12 (G6_ALZHEIMER, 13,964 cases) (same variant; GWAS effect from FinnGen R12 full summary statistics (marginal effect)): Wald ratio -0.796, one-sided p = 0.0067 in the discovery direction.
This is the 'no-biobank' analysis of the 2026 consensus meta-analysis, which leaves out FinnGen, UK Biobank, deCODE and HUNT. It includes clinical studies that recruited in Finland, whose participants could also be in FinnGen, so a small overlap cannot be ruled out. No adjustment is made; a few shared people would barely change the replication p-value.
Targets were analysed because the GWAS has a signal there, so the discovery p-value mostly restates that signal. The new information is the direction and whether a second GWAS agrees.
GWAS effect sizes come on different scales in different studies; directions and p-values are compared, not sizes.
Threshold 0.00833 two-sided = 0.05 / 6 targets, fixed for this data version.
All numbers
{
"mode": "two_sided",
"instruments": [
{
"gwas_set": "16180a9a0700c780382ef28677938ecb",
"qtl_set": "5969efaa514a4f78e6d06a30fe0073e8",
"variant": "6_41161469_C_T",
"rsid": "rs143332484",
"qtl_study": "UKB_PPP_EUR_TREM2_Q9NZC2_OID20731_v1",
"project": "UKB_PPP_EUR",
"tissue": "blood plasma",
"condition": null,
"qtl_type": "pqtl",
"class": "plasma_protein",
"h4": 1,
"clpp": 0.9981,
"rule": "gwas_lead",
"route": null,
"rep_set": null,
"source": null,
"pip_g": 0.9980556743610776,
"pip_q": 1,
"sg_src": "p-value",
"bg": 0.0238966,
"sg": 0.00257225,
"bq": -0.235698,
"sq": 0.00613677,
"ratio": -0.101387,
"se": 0.0109133,
"ci": [
-0.122777,
-0.0799966
],
"z": -9.29017,
"se2": 0.011228,
"z2": -9.02977,
"F": 1475.14,
"zq": -38.4075,
"direction": -1
},
{
"gwas_set": "41e5cf2cd0d30def3fd079a7af8d1b6d",
"qtl_set": "0ad62352a0fcff260267ac77e4fabbf7",
"variant": "6_41161514_C_T",
"rsid": "rs75932628",
"qtl_study": "UKB_PPP_EUR_TREM2_Q9NZC2_OID20731_v1",
"project": "UKB_PPP_EUR",
"tissue": "blood plasma",
"condition": null,
"qtl_type": "pqtl",
"class": "plasma_protein",
"h4": 0.9999,
"clpp": 0.943,
"rule": "gwas_lead",
"route": null,
"rep_set": null,
"source": null,
"pip_g": 0.9475823911103441,
"pip_q": 0.9951990989111235,
"sg_src": "p-value",
"bg": 0.0272447,
"sg": 0.00268974,
"bq": 0.0991243,
"sq": 0.00533033,
"ratio": 0.274853,
"se": 0.027135,
"ci": [
0.221669,
0.328038
],
"z": 10.1291,
"se2": 0.0308992,
"z2": 8.89517,
"F": 345.822,
"zq": 18.5963,
"direction": 1
},
{
"gwas_set": "4d89e9d8ae6dc2f20a3287845da86405",
"qtl_set": "e1fea5b3f198c16deabff2eda329ce11",
"variant": "6_41164934_TG_T",
"rsid": "rs61599288",
"qtl_study": "UKB_PPP_EUR_TREM2_Q9NZC2_OID20731_v1",
"project": "UKB_PPP_EUR",
"tissue": "blood plasma",
"condition": null,
"qtl_type": "pqtl",
"class": "plasma_protein",
"h4": 0.92,
"clpp": 0.0103,
"rule": "qtl_lead",
"route": null,
"rep_set": null,
"source": null,
"pip_g": 0.009762747436247252,
"pip_q": 0.07426838363689132,
"sg_src": "p-value",
"bg": 0.010876,
"sg": 0.00252018,
"bq": -0.0279156,
"sq": 0.00415112,
"ratio": -0.389603,
"se": 0.0902785,
"ci": [
-0.566549,
-0.212657
],
"z": -4.31557,
"se2": 0.107269,
"z2": -3.63201,
"F": 45.2236,
"zq": -6.72485,
"direction": -1
}
],
"n_instruments": 3,
"primary": {
"gwas_set": "16180a9a0700c780382ef28677938ecb",
"variant": "6_41161469_C_T",
"rsid": "rs143332484",
"qtl_study": "UKB_PPP_EUR_TREM2_Q9NZC2_OID20731_v1",
"project": "UKB_PPP_EUR",
"tissue": "blood plasma",
"condition": null,
"qtl_type": "pqtl",
"class": "plasma_protein",
"h4": 1,
"clpp": 0.9981,
"ratio": -0.101387,
"se": 0.0109133,
"ci": [
-0.122777,
-0.0799966
],
"z": -9.29017,
"se2": 0.011228,
"z2": -9.02977,
"F": 1475.14,
"direction": -1,
"rule": "gwas_lead",
"bg": 0.0238966,
"sg": 0.00257225,
"bq": -0.235698,
"sq": 0.00613677,
"sg_src": "p-value"
},
"direction": -1,
"direction_text": "more TREM2, lower risk",
"p_two_sided": 1.54042e-20,
"alpha": 0.00833333,
"discovery_passed": true,
"replication": {
"gwas_set": "16180a9a0700c780382ef28677938ecb",
"qtl_set": "5969efaa514a4f78e6d06a30fe0073e8",
"variant": "6_41161469_C_T",
"rsid": "rs143332484",
"qtl_study": "UKB_PPP_EUR_TREM2_Q9NZC2_OID20731_v1",
"project": "UKB_PPP_EUR",
"tissue": "blood plasma",
"condition": null,
"qtl_type": "pqtl",
"class": "plasma_protein",
"h4": 1,
"clpp": 0.9981,
"rule": "gwas_lead",
"route": "same_variant",
"rep_set": null,
"source": "FinnGen R12 full summary statistics (marginal effect)",
"pip_g": null,
"pip_q": 1,
"sg_src": "reported",
"allele_match": "same",
"af_rep": 0.00775058,
"af_ref": 0.007104490662669415,
"bg": 0.187601,
"sg": 0.0758313,
"bq": -0.235698,
"sq": 0.00613677,
"ratio": -0.795938,
"se": 0.321731,
"ci": [
-1.42653,
-0.165345
],
"z": -2.47392,
"se2": 0.322398,
"z2": -2.46881,
"F": 1475.14,
"zq": -38.4075,
"direction": -1,
"p_one_sided": 0.00668198,
"agrees": true
},
"consistency": {
"by_class": {
"plasma_protein": {
"n": 1,
"same": 1,
"opposite": 0,
"tied": 0,
"opposite_examples": []
}
},
"datasets": 1,
"same": 1,
"share_same": 1.0,
"other_signals": [
{
"gwas_set": "41e5cf2cd0d30def3fd079a7af8d1b6d",
"direction": 1,
"votes": 1
},
{
"gwas_set": "4d89e9d8ae6dc2f20a3287845da86405",
"direction": -1,
"votes": -1
}
]
},
"verdict": "direction_replicated",
"template": "target_genetics",
"runner": "tests-v1"
}Human challenges
Anyone can question this result: a claim that was read wrongly, a patient group the paper did use, a wrong gene or direction, or a problem with the data. A person reviews each challenge. Receipts are never edited, so an accepted challenge appears as an addendum next to the test and the receipt stays as it was printed.
- No challenges yet.
Challenge this result
Receipt #531
Printed when the review finished, 12 Oct 2026, 05:00 UTC. Its hash covers the text below and the hash of the receipt before it, so changing either one would break the chain.
- Hash
- 1c1cf1b5f4d46d7d0f83c780861e42ebc5e8214f7bf7463514038b637cb0df83
- Previous
- 37bf5dd0666b4e65414acda544d81578e3d5a09ee49c846dc5fa829cf69342cf
{"challenges":[{"agent":"tissue","text":"No brain QTL colocalises at this signal; the direction comes from plasma protein (blood plasma), which may not reflect TREM2 in the brain."},{"agent":"consistency","text":"1 other GWAS signal(s) near TREM2 colocalise with TREM2 QTLs in the opposite direction, so the gene-level direction is not settled."},{"agent":"instrument","text":"The instrument (rs143332484) is a missense variant in TREM2. A pQTL at a coding variant can reflect antibody or aptamer binding rather than protein amount, and the variant can change protein function."}],"disease":"alzheimers","hypothesis_id":530,"notes":["Primary estimate: UKB_PPP_EUR blood plasma (protein), H4 1.00, CLPP 0.998.","Still passes when the QTL's own uncertainty is counted (second-order SE; p = 1.7e-19).","QTL datasets at this signal that agree with the primary direction: plasma protein 1 of 1.","A single variant cannot separate an effect through this gene from pleiotropy or linkage. Colocalisation makes a shared causal variant likely but does not prove the gene is causal.","Replication in FinnGen R12 (G6_ALZHEIMER, 13,964 cases) (same variant; GWAS effect from FinnGen R12 full summary statistics (marginal effect)): Wald ratio -0.796, one-sided p = 0.0067 in the discovery direction.","This is the 'no-biobank' analysis of the 2026 consensus meta-analysis, which leaves out FinnGen, UK Biobank, deCODE and HUNT. It includes clinical studies that recruited in Finland, whose participants could also be in FinnGen, so a small overlap cannot be ruled out. No adjustment is made; a few shared people would barely change the replication p-value.","Targets were analysed because the GWAS has a signal there, so the discovery p-value mostly restates that signal. The new information is the direction and whether a second GWAS agrees.","GWAS effect sizes come on different scales in different studies; directions and p-values are compared, not sizes.","Threshold 0.00833 two-sided = 0.05 / 6 targets, fixed for this data version."],"prereg_hash":"b4db69e0844be0e04572cc80e1e85c81c08e1a7a7693160a8787b738982ece37","printed_at":1791781247.257,"registered_at":1791781222.4928105,"reviewed_by":"house:alzheimers:skeptic","statement":"Genetically higher TREM2 levels change the risk of Alzheimer's disease; the direction says what a drug would need to do to TREM2.","status":"challenged","summary":"more TREM2, lower risk: Wald ratio -0.101 (95% CI -0.123 to -0.08), p=1.5e-20 [blood plasma, protein]; replication ratio -0.796, one-sided p=0.0067 -> direction replicated","template":"target_genetics","tested_by":"house:alzheimers:runner","verdict":"direction_replicated"}
Your browser recomputes the hash, fetches the previous receipt and compares the receipt with this page.
To check every receipt at once, use Check the chain on the main page.